Tolerance to GLP-1s: Does It Happen?

If you have ever taken a medication that worked beautifully for a few months and then quietly stopped, it is reasonable to ask whether GLP-1 receptor agonists like semaglutide or tirzepatide will do the same. Pharmacological tolerance, where the same dose produces a smaller effect over time, is real for many drug classes. So does it happen here?

What the longer trials show

The picture is more reassuring than tolerance theory might predict, with one important caveat. In the STEP 1 obesity trial of weekly semaglutide 2.4 mg, mean weight loss reached about 17.3% by week 68 and then settled rather than rebounding while people stayed on the drug. In SURMOUNT-4, participants who continued tirzepatide kept losing weight (a further 5.5% from week 36 to week 88) while those switched to placebo regained. That plateau-then-hold pattern is usually read not as the drug failing, but as the body reaching a new equilibrium at a lower weight.

The plateau most people hit is probably the body finding a new set point, not the receptor going numb. The two look similar on a scale but mean different things.

True receptor desensitization, the cellular machinery becoming less responsive to repeated stimulation, is something researchers watch for, but the published multi-year data does not show the appetite effect evaporating in people who keep taking the medication at a stable dose.

A few things that get mistaken for tolerance

• Dose timing. Many regimens titrate up over months; a plateau can coincide with reaching the top dose, which is easy to misread.
• Behavioral drift. Old eating patterns can slowly return as the novelty fades, blunting results without any change in the drug.
• Reaching a defended floor. Sometimes the effect “stops” because the person has reached a weight their physiology holds.

The sharper, well-documented phenomenon is what happens after stopping. In the STEP 1 trial extension, participants regained about two-thirds of their lost weight in the year after withdrawal. That is rebound, not tolerance: the drug still works; you have just removed it.

The takeaway

On current evidence, classic pharmacological tolerance to GLP-1s does not appear to be the main story. The slowdown most people experience looks more like a new physiological set point than a fading drug. The more practical concern is what happens when treatment ends, since the appetite signal these drugs provide mostly disappears with them. Individual responses vary more than averages suggest.

Sources

• Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension (Diabetes, Obesity and Metabolism, 2022)
• Continued Treatment With Tirzepatide for Maintenance of Weight Reduction: The SURMOUNT-4 Randomized Clinical Trial (JAMA, 2024)